Archive


Category: Alligator Bioscience

  • Alligator Bioscience Submits CTA for the P-II OPTIMIZE-1 Study of Mitazalimab

    Shots: Alligator reports that it has submitted a CTA application to the relevant regulatory authorities to start a P-II efficacy study of its CD40 targeting antibody mitazalimab Upcoming P-II OPTIMIZE-1 study is assessing mitazalimab + CT (mFolfirinox) in patients with metastatic pancreatic cancer and will be performed at several clinics in Europe involve up to […]